Clinical trial

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

NCT05130255

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-11-17

PhasePHASE1

Study timeline

Study start (actual)2022-11-17Date precision: day

Registry last updated2026-06-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

SCLCunresolved

Malignant Melanomaunresolved

Sarcomaunresolved

High Risk Neuroblastomaunresolved

Interventions

GD2-SADA (0.3 mg/kg) and 177Lu-DOTA (30 mCi)DRUG

GD2-SADA (3 mg/kg) 177Lu-DOTA (30 mCi)DRUG

GD2-SADA (0.3 mg/kg) 177Lu-DOTA (200 mCi)DRUG

GD2-SADA (1 mg/kg) 177Lu-DOTA (200 mCi)DRUG

GD2-SADA (3 mg/kg) 177Lu-DOTA (200 mCi)DRUG

GD2-SADA (1 mg/kg) 177Lu-DOTA (30 mCi)DRUG

GD2-SADA (1 mg/kg) 177Lu-DOTA (100 mCi)DRUG

Sponsors & collaborators

Y-mAbs Therapeuticslead sponsor

Mapped research locations

New YorkNew York, United States1 ChicagoIllinois, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1 MadisonWisconsin, United States1 ScottsdaleArizona, United States1 DuarteCalifornia, United States1 Grand RapidsMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05130255 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.